Celltrion Chairman Seo Jeong-jin has confirmed that the South Korean drugmaker has decided to build its third plant outside of South Korea and expects to start construction by year-end. More: Celltrion's Seo says company will build next plant outside of
read moreSkittish investors grew increasingly concerned last year that Merck & Co. couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial of previously untreated patients. But on Tuesday, the pharma giant silenced its doubters. More: Merck extends all-important lung-cancer
read moreGood news for pharma’s pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, and drugmakers are finding safer havens in oncology and rare diseases, a new analysis shows. More: How to sidestep pricing
read moreHere are some other pharma industry stories we’re following today. More: News of Note—Thermo Fisher and Flexion; Indian inspections of U.S. facilities Source: fierce
read moreNovartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis. More: Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial Source: News
read moreThe rising tide of accident and emergency attendances is being driven by long-term health conditions rather than a lack of GP provision, concludes a study by Queen Mary University of London. More: A&E pressures not down to GP access, study
read more© 1994 - 2026 B.M. Pharmaceuticals